OP White Papers - random

  1. Guiding Principles For Process Development And IND Readiness 7/25/2025

    Observe how a milestone-driven risk management strategy streamlines cell therapy development, reduces uncertainty, and aligns early decisions with long-term commercialization and regulatory success.

  2. Seasonal Vaccine Manufacturing: 3 Areas To Evaluate When Selecting A Partner 10/16/2024

    Experienced outsourcing partners will have the right facility and technical capabilities, a culture of speed and execution, and shared expectations and commitment to continuous improvement.

  3. Three-Dimensional Linkage Analysis With Digital PCR For Genome Integrity 2/14/2025

    A cost-effective approach with a comprehensive AAV analytical package holds the potential to advance the application of rAAV in cell and gene therapy for the treatment of human diseases.

  4. Drug Substance For Early Clinical Phase Initiation 5/6/2026

    Explore how proactive nitrosamine impurity risk assessment protects early clinical drug supply, minimizes development delays, and enables confident progression to first‑in‑human studies.

  5. The Effect Of Conventional Cooling Versus Controlled Ice Nucleation On Primary Drying Time 4/1/2026

    See how controlled ice nucleation shortens lyophilization cycles, supports higher drying temperatures, and reduces complexity for amorphous and mixed formulations without sacrificing quality.

  6. Untapped Potential In Animal Health Innovation 5/26/2026

    Animal health innovation is driving rapid market growth, fueled by rising demand and complexity, creating opportunities for advanced therapies, sustainability, and better disease management.

  7. Spray Dried Biologics For Injectable Dosage Forms 5/15/2026

    Spray drying enables scalable production of stable, high‑concentration biologics as sterile powders, improving delivery, reducing costs, and overcoming limitations of traditional freeze‑drying methods.

  8. Unlocking Durable Allogeneic Cell Therapy 5/13/2026

    Advances in genome engineering and immune evasion are enabling scalable, durable allogeneic cell therapies, overcoming rejection challenges and expanding potential treatments across diverse diseases.

  9. Redefining Biomanufacturing For Personalized Cancer Vaccines 4/24/2026

    Personalized cancer vaccines need fast, flexible manufacturing. Cell‑free synthetic DNA enables rapid, small‑batch mRNA production, supporting individualized therapies beyond plasmid‑based limits.

  10. Systematic Strategy To Reduce The Cost Of Goods Sold 3/26/2026

    Learn key ways to cut biologics manufacturing costs through smarter process design, material choices, and supply resilience — driving more efficient, reliable, and commercially sustainable production.